NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APTX stock has increased by 62.6% and is now trading at $3.95.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aptinyx.

Aptinyx will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Aptinyx Inc (NASDAQ:APTX) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The firm earned $0.82 million during the quarter, compared to analyst estimates of $0.91 million. Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%.
View Aptinyx's earnings history.

6 analysts have issued 1-year price targets for Aptinyx's stock. Their forecasts range from $7.00 to $15.00. On average, they expect Aptinyx's share price to reach $9.67 in the next year. This suggests a possible upside of 144.7% from the stock's current price.
View analysts' price targets for Aptinyx.

News stories about APTX stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aptinyx earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Aptinyx.

Aptinyx saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 912,900 shares, a drop of 10.5% from the July 15th total of 1,020,000 shares. Based on an average daily trading volume, of 421,500 shares, the short-interest ratio is presently 2.2 days. Approximately 4.1% of the shares of the company are short sold.
View Aptinyx's Short Interest.

Some companies that are related to Aptinyx include Legend Biotech (AMTI), ImmunoGen (IMGN), Passage Bio (KROS), ZIOPHARM Oncology (ZIOP), Tricida (TCDA), Akouos (AKUS), Frequency Therapeutics (FREQ), Eagle Pharmaceuticals (EGRX), Flexion Therapeutics (FLXN), Vanda Pharmaceuticals (VNDA), Trillium Therapeutics (TRIL), G1 Therapeutics (GTHX), Aprea Therapeutics (APRE), Stemline Therapeutics (STML) and Collegium Pharmaceutical (COLL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.45%), Meridian Wealth Management LLC (0.07%), New York State Common Retirement Fund (0.05%), Leap Investments LP (0.03%) and UBS Group AG (0.02%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen.
View institutional ownership trends for Aptinyx.

APTX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meridian Wealth Management LLC, New York State Common Retirement Fund, Leap Investments LP, and UBS Group AG. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen.
View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.95.

Aptinyx has a market capitalization of $180.36 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]